Scholar Rock Holding (SRRK) Change in Acquisitions & Divestments (2017 - 2026)
Scholar Rock Holding's (SRRK) quarterly Change in Acquisitions & Divestments came in at $20.0 million in Q1 2026, down 78.47% year-on-year from $92.9 million in Q1 2025, and down 48.72% quarter-over-quarter from $39.0 million in Q4 2025.
Scholar Rock Holding (SRRK) Change in Acquisitions & Divestments (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Change in Acquisitions & Divestments history runs 10 years deep, the most recent figure standing at $20.0 million for Q1 2026.
- On a quarterly basis, Change in Acquisitions & Divestments fell 78.47% year-over-year to $20.0 million in Q1 2026; TTM through Mar 2026 was $244.4 million, a 1.12% increase from a year earlier, with the FY2025 full-year figure at $317.3 million, up 46.09% from the prior year.
- Change in Acquisitions & Divestments declined to $20.0 million in Q1 2026 per SRRK's latest filing, from $39.0 million in the prior quarter.
- Across five years, Change in Acquisitions & Divestments topped out at $106.9 million in Q2 2025 and bottomed at $10.0 million in Q1 2022.
- The 5-year median for Change in Acquisitions & Divestments is $68.4 million (2024), against an average of $59.8 million.
- Across the five-year window, Change in Acquisitions & Divestments plunged 81.82% in 2022 and jumped 800.0% in 2023, its largest moves.
- Year by year, Change in Acquisitions & Divestments stood at $10.0 million in 2022, then soared by 690.0% to $79.0 million in 2023, then slumped by 80.89% to $15.1 million in 2024, then soared by 158.28% to $39.0 million in 2025, then slumped by 48.72% to $20.0 million in 2026.
- Per Business Quant, the three latest SRRK Change in Acquisitions & Divestments figures stand at $20.0 million (Q1 2026), $39.0 million (Q4 2025), and $78.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.62 Bn | 466.83 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn |
| 10 | Scholar Rock Holding | 6.35 Bn | 6.35 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.00 Mn |
| Mar 31, 2026 | 20.00 Mn |
| Dec 31, 2025 | 39.00 Mn |
| Dec 31, 2025 | 39.00 Mn |
| Sep 30, 2025 | 78.50 Mn |
| Sep 30, 2025 | 78.50 Mn |
| Jun 30, 2025 | 106.90 Mn |
| Jun 30, 2025 | 106.90 Mn |
| Mar 31, 2025 | 92.90 Mn |
| Mar 31, 2025 | 92.90 Mn |
| Dec 31, 2024 | 15.10 Mn |
| Dec 31, 2024 | 15.10 Mn |
| Sep 30, 2024 | 49.60 Mn |
| Sep 30, 2024 | 49.60 Mn |
| Jun 30, 2024 | 84.10 Mn |
| Jun 30, 2024 | 84.10 Mn |
| Mar 31, 2024 | 68.40 Mn |
| Mar 31, 2024 | 68.40 Mn |
| Dec 31, 2023 | 79.00 Mn |
| Dec 31, 2023 | 79.00 Mn |